In contrast, low levels of LAMP2 expression benefit immunotherapy, as patients with a low level of LAMP2 responded better to the ICB treatment than those with a high level of LAMP2 (Supplementary Fig. 7e) in an anti-PD1-treated melanoma cohort48,50. Here, LAMP2 is linked to melanoma.